The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein ...

Genetics and drug discovery had its origins in the 1980s with the development of positional cloning technology—that is, using genetic markers to map and identify the genes responsible for Mendelian ...

Targeted rewriting of the epigenome promises to overcome several challenges in direct gene editing in patient therapies.

The update was requested by the FDA based on data supporting the significant LDL-C lowering abilities of PCSK-targeting therapies.

Leqvio can now be used alone, without addition of statin therapy, as adjunct to diet and exercise for LDL-C reduction in patients with hypercholesterolemia (high ...